T-cell enhancing scaffold illustration (IMAGE)
Caption
T-cell enhancing scaffolds can be locally injected under the skin following CAR-T cell therapy, and allowcirculating CAR-T cells to infiltrate their 3-dimensional porous scaffold structure. There, CAR-T cells become activated and are induced to proliferate before they eventually egress into the blood circulation to carry out systemic antitumor functions. As shown on the right, TES release the interleukin IL-2, which stimulates CAR-T cells to multiply, and anti-CD3 and anti-CD28, two antibodies that, similar to tumor antigens presented by an antigen-presenting cell (APC) of the immune system, stimulate CAR-T cells to differentiate into tumor cell-killing “effector T cells.”
Credit
Wyss Institute at Harvard University
Usage Restrictions
None
License
Original content